Active Biotech (Sweden) Performance
| ACTI Stock | SEK 0.04 0.0005 1.32% |
The firm shows a Beta (market volatility) of -1.21, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Active Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Active Biotech is expected to outperform it. At this point, Active Biotech AB has a negative expected return of -0.81%. Please make sure to confirm Active Biotech's maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if Active Biotech AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Active Biotech AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 26.2 M | |
| Free Cash Flow | -46.2 M |
Active |
Active Biotech Relative Risk vs. Return Landscape
If you would invest 6.46 in Active Biotech AB on November 21, 2025 and sell it today you would lose (2.61) from holding Active Biotech AB or give up 40.4% of portfolio value over 90 days. Active Biotech AB is generating negative expected returns and assumes 3.539% volatility on return distribution over the 90 days horizon. Simply put, 31% of stocks are less volatile than Active, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Active Biotech Target Price Odds to finish over Current Price
The tendency of Active Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.04 | 90 days | 0.04 | about 86.87 |
Based on a normal probability distribution, the odds of Active Biotech to move above the current price in 90 days from now is about 86.87 (This Active Biotech AB probability density function shows the probability of Active Stock to fall within a particular range of prices over 90 days) .
Active Biotech Price Density |
| Price |
Predictive Modules for Active Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Active Biotech AB. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Active Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Active Biotech is not an exception. The market had few large corrections towards the Active Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Active Biotech AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Active Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.66 | |
β | Beta against Dow Jones | -1.21 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.21 |
Active Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Active Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Active Biotech AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Active Biotech AB generated a negative expected return over the last 90 days | |
| Active Biotech AB has some characteristics of a very speculative penny stock | |
| Active Biotech AB has high historical volatility and very poor performance | |
| Active Biotech AB has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (49.83 M) with profit before overhead, payroll, taxes, and interest of 6.72 M. | |
| Active Biotech AB has accumulated about 53.13 M in cash with (46.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 46.0% of the company shares are held by company insiders |
Active Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Active Stock often depends not only on the future outlook of the current and potential Active Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Active Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 211.9 M | |
| Cash And Short Term Investments | 53.1 M |
Active Biotech Fundamentals Growth
Active Stock prices reflect investors' perceptions of the future prospects and financial health of Active Biotech, and Active Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Active Stock performance.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 224.92 M | |||
| Shares Outstanding | 264.89 M | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 5.63 X | |||
| Price To Sales | 29.72 X | |||
| EBITDA | (48.52 M) | |||
| Cash And Equivalents | 53.13 M | |||
| Cash Per Share | 0.11 X | |||
| Total Debt | 200 K | |||
| Debt To Equity | 268.10 % | |||
| Book Value Per Share | 0.13 X | |||
| Cash Flow From Operations | (46.17 M) | |||
| Earnings Per Share | (0.25) X | |||
| Total Asset | 56.8 M | |||
| Current Asset | 65 M | |||
| Current Liabilities | 29 M | |||
About Active Biotech Performance
Assessing Active Biotech's fundamental ratios provides investors with valuable insights into Active Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Active Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Active Biotech AB , a biotechnology company, develops drugs for the treatment of neurodegenerative diseases, autoimmunityinflammatory, and cancer. Active Biotech AB was incorporated in 1982 and is based in Lund, Sweden. Active Biotech operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.Things to note about Active Biotech AB performance evaluation
Checking the ongoing alerts about Active Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Active Biotech AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Active Biotech AB generated a negative expected return over the last 90 days | |
| Active Biotech AB has some characteristics of a very speculative penny stock | |
| Active Biotech AB has high historical volatility and very poor performance | |
| Active Biotech AB has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (49.83 M) with profit before overhead, payroll, taxes, and interest of 6.72 M. | |
| Active Biotech AB has accumulated about 53.13 M in cash with (46.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 46.0% of the company shares are held by company insiders |
- Analyzing Active Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Active Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Active Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Active Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Active Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Active Biotech's stock. These opinions can provide insight into Active Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Active Stock Analysis
When running Active Biotech's price analysis, check to measure Active Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Active Biotech is operating at the current time. Most of Active Biotech's value examination focuses on studying past and present price action to predict the probability of Active Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Active Biotech's price. Additionally, you may evaluate how the addition of Active Biotech to your portfolios can decrease your overall portfolio volatility.